Boguslawa Pietrzak
Overview
Explore the profile of Boguslawa Pietrzak including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
28
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zwierzynska E, Klimczak M, Nasiadek M, Stragierowicz J, Pietrzak B
Pharmacol Rep
. 2024 Oct;
76(6):1363-1376.
PMID: 39352642
Background: Ethanol disrupts brain activity and memory. There is evidence supporting the beneficial effect of levetiracetam on alcohol consumption. Therefore, the aim of the study was to examine whether levetiracetam...
2.
Zwierzynska E, Pietrzak B
Pharmacol Rep
. 2024 Jan;
76(1):86-97.
PMID: 38182968
Background: Memory deficits and anxiety symptoms are undesirable effects that occur in epilepsy patients. They may be associated with the pathophysiology of the disease but also with anticonvulsant therapy. Brivaracetam...
3.
Pietrzak B, Krupa-Burtnik A, Zwierzynska E
Int J Environ Res Public Health
. 2023 Feb;
20(3).
PMID: 36767184
Antiepileptic drugs might be useful in the treatment of alcohol use disorder. One of these drugs is zonisamide, which has been found to decrease alcohol intake and cravings. An important...
4.
Zwierzynska E, Pietrzak B
Epilepsy Behav
. 2022 Sep;
136:108917.
PMID: 36150302
Objective: One of the newest antiseizure medication is levetiracetam (LEV). It might be effective in various indications, not only related to convulsions. Central nervous system disorders are common during anticonvulsant...
5.
Zwierzynska E, Pietrzak B
Epilepsy Behav
. 2021 Nov;
125:108401.
PMID: 34775245
Objective: Lacosamide (LC) belongs to a new generation of antiepileptic drugs (AEDs) and demonstrates unique mechanism of action. The drug also shows neuroprotective activity on the hippocampus. In this study,...
6.
Zwierzynska E, Krupa-Burtnik A, Pietrzak B
Pharmacol Rep
. 2021 Jan;
73(2):480-489.
PMID: 33385172
Background: Retigabine belongs to the novel generation of antiepileptic drugs but its complex mechanism of action causes that the drug might be effective in other diseases, for instance, alcohol dependence....
7.
Krupa-Burtnik A, Zwierzynska E, Pietrzak B
Epilepsy Behav
. 2019 Nov;
102:106659.
PMID: 31756621
Objective: Zonisamide is an antiepileptic drug with a perspective of a broader use. Although it is regarded as a relatively safe drug, zonisamide might cause disorders of the central nervous...
8.
Zwierzynska E, Krupa-Burtnik A, Wiesner A, Pietrzak B
Alcohol Alcohol
. 2018 Jul;
53(6):688-698.
PMID: 30020409
Aims: Topiramate causes the inhibition of alcohol consumption in addicts but the mechanism of this action has not been fully understood yet. Nowadays, it seems that memory may have a...
9.
Zwierzynska E, Krupa-Burtnik A, Pietrzak B
Epilepsy Behav
. 2017 Sep;
75:170-175.
PMID: 28866337
Objective: Retigabine is a novel antiepileptic drug with a unique and complex mechanism of action which allows its use in many diseases associated with impaired neuronal activity. This study sought...
10.
Krupa-Burtnik A, Zwierzynska E, Kordala A, Pietrzak B
Alcohol Alcohol
. 2017 Mar;
52(3):282-288.
PMID: 28339635
Aims: Zonisamide is a new anti-epileptic drug whose mechanism of action is associated with neurotransmission systems also involved in the pathogenesis of addiction. Recently, the role of memory processes and...